50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,632.92 (-2.32%)
DOW   29,155.75 (-1.78%)
QQQ   271.38 (-3.06%)
AAPL   143.11 (-4.49%)
MSFT   235.34 (-2.38%)
META   136.24 (-3.79%)
GOOGL   96.54 (-3.51%)
AMZN   114.08 (-3.33%)
TSLA   272.84 (-5.20%)
NVDA   121.53 (-4.58%)
NIO   16.08 (-7.21%)
BABA   77.46 (-4.36%)
AMD   64.97 (-4.96%)
T   15.51 (-2.02%)
MU   49.39 (-3.16%)
CGC   2.82 (-7.24%)
F   11.49 (-5.67%)
GE   62.38 (-3.23%)
DIS   97.30 (-2.11%)
AMC   7.26 (-5.35%)
PYPL   89.33 (-1.96%)
PFE   43.98 (-1.01%)
NFLX   241.85 (-1.37%)
S&P 500   3,632.92 (-2.32%)
DOW   29,155.75 (-1.78%)
QQQ   271.38 (-3.06%)
AAPL   143.11 (-4.49%)
MSFT   235.34 (-2.38%)
META   136.24 (-3.79%)
GOOGL   96.54 (-3.51%)
AMZN   114.08 (-3.33%)
TSLA   272.84 (-5.20%)
NVDA   121.53 (-4.58%)
NIO   16.08 (-7.21%)
BABA   77.46 (-4.36%)
AMD   64.97 (-4.96%)
T   15.51 (-2.02%)
MU   49.39 (-3.16%)
CGC   2.82 (-7.24%)
F   11.49 (-5.67%)
GE   62.38 (-3.23%)
DIS   97.30 (-2.11%)
AMC   7.26 (-5.35%)
PYPL   89.33 (-1.96%)
PFE   43.98 (-1.01%)
NFLX   241.85 (-1.37%)
S&P 500   3,632.92 (-2.32%)
DOW   29,155.75 (-1.78%)
QQQ   271.38 (-3.06%)
AAPL   143.11 (-4.49%)
MSFT   235.34 (-2.38%)
META   136.24 (-3.79%)
GOOGL   96.54 (-3.51%)
AMZN   114.08 (-3.33%)
TSLA   272.84 (-5.20%)
NVDA   121.53 (-4.58%)
NIO   16.08 (-7.21%)
BABA   77.46 (-4.36%)
AMD   64.97 (-4.96%)
T   15.51 (-2.02%)
MU   49.39 (-3.16%)
CGC   2.82 (-7.24%)
F   11.49 (-5.67%)
GE   62.38 (-3.23%)
DIS   97.30 (-2.11%)
AMC   7.26 (-5.35%)
PYPL   89.33 (-1.96%)
PFE   43.98 (-1.01%)
NFLX   241.85 (-1.37%)
S&P 500   3,632.92 (-2.32%)
DOW   29,155.75 (-1.78%)
QQQ   271.38 (-3.06%)
AAPL   143.11 (-4.49%)
MSFT   235.34 (-2.38%)
META   136.24 (-3.79%)
GOOGL   96.54 (-3.51%)
AMZN   114.08 (-3.33%)
TSLA   272.84 (-5.20%)
NVDA   121.53 (-4.58%)
NIO   16.08 (-7.21%)
BABA   77.46 (-4.36%)
AMD   64.97 (-4.96%)
T   15.51 (-2.02%)
MU   49.39 (-3.16%)
CGC   2.82 (-7.24%)
F   11.49 (-5.67%)
GE   62.38 (-3.23%)
DIS   97.30 (-2.11%)
AMC   7.26 (-5.35%)
PYPL   89.33 (-1.96%)
PFE   43.98 (-1.01%)
NFLX   241.85 (-1.37%)
OTCMKTS:KHTRF

Knight Therapeutics - KHTRF Stock Forecast, Price & News

$4.03
-0.62 (-13.35%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$4.02
$4.03
50-Day Range
$4.17
$4.71
52-Week Range
$3.66
$4.77
Volume
580 shs
Average Volume
2,108 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.55
KHTRF stock logo

About Knight Therapeutics (OTCMKTS:KHTRF) Stock

Knight Therapeutics Inc., a specialty pharmaceutical company, develops, acquires, in-licenses, out-licenses, markets, and distributes pharmaceutical and consumer health products, and medical devices in Canada, Latin America, and internationally. It offers Nerlynx for extended adjuvant breast cancer and metastatic breast cancer; Tafasitamab for relapsed or refractory diffuse large B-cell lymphoma; Pemigatinib to treat metastatic cholangiocarcinoma; Trelstar for advanced prostate cancer and for pain associated with endometriosis; Vidaza for myelodysplastic syndrome; Abraxane for metastatic pancreatic adenocarcinoma; Halaven for metastatic breast cancer and doft tissue sarcoma; and Lenvima for differentiated thyroid cancer, advanced renal cell cancer, and unresectable hepatocellular carcinoma. The company also provides Ladevina for multiple myeloma, myelodysplastic syndrome, mantle cell lymphoma, and follicular lymphoma; Zyvalix for metastatic prostate cancer; Karfib for relapsed or refractory multiple myeloma; Leprid for advanced prostate cancer; Rembre for chronic myeloid leukemia; Ambisome and Cresemba for fungal infection; Impavido for leishmaniasis; Exelon for mild to moderately severe dementia; and Ibsrela for the treatment of irritable bowel syndrome with constipation. In addition, it offers Salofalk for ulcerative colitis; Ursofalk to treat biliary cirrhosis; Imvexxy for moderate to severe dyspareunia; Bijuva for moderate to severe vasomotor symptoms associated with menopause in women with intact uteri; Fibridoner to treat idiopathic pulmonary fibrosis; Toliscrin DPI for pseudomonas aeruginosa lung infection in patients with cystic fibrosis; Toliscrin 1-2 for severe acute or resistant chronic infections; and Tobradosa Haler for chronic lung infections. Further, the company finances other life science companies; and invests in life sciences venture capital funds. Knight Therapeutics Inc. was incorporated in 2013 and is headquartered in Montreal, Canada.

Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KHTRF Stock News Headlines

Knight Therapeutics reports Q4 results
Knight Therapeutics Inc (KHTRF)
Is Knight Therapeutics (TSE:GUD) Using Too Much Debt?
Knight Therapeutics Reports Third Quarter 2021
What Wall Street expects from Knight Therapeutics's earnings
Knight Therapeutics Reports Second Quarter 2021
IIROC Trade Resumption - GUD
See More Headlines
Receive KHTRF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Knight Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KHTRF Company Calendar

Today
9/29/2022
Next Earnings (Estimated)
11/09/2022

Industry, Sector and Symbol

Industry
Drug Manufacturers - Specialty & Generic
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:KHTRF
CIK
N/A
Fax
N/A
Employees
660
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$6.55
High Stock Price Forecast
$7.50
Low Stock Price Forecast
$5.40
Forecasted Upside/Downside
+62.7%
Consensus Rating
Hold
Rating Score (0-4)
2.00
Research Coverage
1 Analysts

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A

Miscellaneous

Free Float
N/A
Optionable
Not Optionable
Beta
N/A

Key Executives

  • Mr. Jonathan Ross Goodman B.A. (Age 53)
    BA, L.L.B., LLB, M.B.A., MBA, Exec. Chairman
    Comp: $348.51k
  • Ms. Samira Sakhia BCom (Age 54)
    CA, CPA, MBA, Pres, CEO & Director
    Comp: $529.49k
  • Mr. Arvind Utchanah
    Chief Financial Officer
  • Ms. Amal Khouri B.Sc.
    M.B.A., Chief Bus. Officer
  • Mr. Jeff Martens
    Global VP Commercial
  • Mr. Leopoldo Bosano
    Vice-Pres of Manufacturing & Operations
  • Ms. Daniela Marino
    Global VP of Legal & Compliance
  • Ms. Susan Caroline Emblem
    Global VP of HR
  • Ms. Jody Engel
    Sr. Director of Bus. Devel.













KHTRF Stock - Frequently Asked Questions

Should I buy or sell Knight Therapeutics stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Knight Therapeutics in the last twelve months. There are currently 1 hold rating for the stock. The consensus among Wall Street analysts is that investors should "hold" KHTRF shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in KHTRF, but not buy additional shares or sell existing shares.
View KHTRF analyst ratings
or view top-rated stocks.

What is Knight Therapeutics' stock price forecast for 2022?

1 brokerages have issued 12-month price targets for Knight Therapeutics' stock. Their KHTRF share price forecasts range from $5.40 to $7.50. On average, they predict the company's share price to reach $6.55 in the next year. This suggests a possible upside of 62.7% from the stock's current price.
View analysts price targets for KHTRF
or view top-rated stocks among Wall Street analysts.

How have KHTRF shares performed in 2022?

Knight Therapeutics' stock was trading at $4.1605 at the beginning of the year. Since then, KHTRF stock has decreased by 3.3% and is now trading at $4.0250.
View the best growth stocks for 2022 here
.

Are investors shorting Knight Therapeutics?

Knight Therapeutics saw a increase in short interest in August. As of August 31st, there was short interest totaling 49,800 shares, an increase of 20.3% from the August 15th total of 41,400 shares. Based on an average trading volume of 400 shares, the short-interest ratio is currently 124.5 days.
View Knight Therapeutics' Short Interest
.

When is Knight Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 9th 2022.
View our KHTRF earnings forecast
.

What is Knight Therapeutics' stock symbol?

Knight Therapeutics trades on the OTCMKTS under the ticker symbol "KHTRF."

How do I buy shares of Knight Therapeutics?

Shares of KHTRF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Knight Therapeutics' stock price today?

One share of KHTRF stock can currently be purchased for approximately $4.03.

How many employees does Knight Therapeutics have?

The company employs 660 workers across the globe.

How can I contact Knight Therapeutics?

Knight Therapeutics' mailing address is 3400 de Maisonneuve West, Montréal, QC H3Z. The official website for the company is www.gud-knight.com. The company can be reached via phone at (514) 484-4483.

This page (OTCMKTS:KHTRF) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.